Skip to Content
Merck
  • Anti-Helicobacter pylori activity of some newly synthesized derivatives of xanthone.

Anti-Helicobacter pylori activity of some newly synthesized derivatives of xanthone.

The Journal of antibiotics (2016-03-31)
Karolina Klesiewicz, Elżbieta Karczewska, Alicja Budak, Henryk Marona, Natalia Szkaradek
ABSTRACT

A series of 20 xanthone derivatives was synthesized and evaluated for anti-Helicobacter pylori (H. pylori) activity. Qualitative and quantitative in vitro tests using the Kirby-Bauer method (agar disc-diffusion method) were performed. The tested compounds were screened against clarithromycin- and/or metronidazole-resistant strains of H. pylori. As a reference, Gram-positive (Staphylococcus aureus) and Gram-negative (Escherichia coli) bacterial strains were examined. On the basis of microbiological assays, xanthones can be considered as potential anti-H. pylori agents. They displayed significant activity against the examined strains, which was higher against the bacteria resistant to metronidazole than clarithromycin. The lowest MIC values ranging up to 20 mg l

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
1-(2-Fluorophenyl)piperazine, 97%
Sigma-Aldrich
3-Chloro-1-propanol, 98%
Sigma-Aldrich
1-(2-Methoxyphenyl)piperazine, 98%
Sigma-Aldrich
Ethyl 1-piperazinecarboxylate, 99%
Sigma-Aldrich
N-tert-Butylmethylamine, 97%